These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 12176585)

  • 1. Replacement of calcineurin inhibitors by mycophenolate mofetil: effect on hemoglobine levels.
    Suwelack B; Kobelt V; Hillebrand U; Gerhardt U; Matzkies F; Hohage H
    Transplant Proc; 2002 Aug; 34(5):1808-9. PubMed ID: 12176585
    [No Abstract]   [Full Text] [Related]  

  • 2. Design and preliminary results of a randomized study on the conversion of treatment with calcineurin inhibitors to mycophenolate mofetil in chronic renal graft failure: effect, on serum cholesterol levels.
    Suwelack B; Gerhardt U; Kobelt V; Hillebrand U; Matzkies F; Hohage H
    Transplant Proc; 2002 Aug; 34(5):1803-5. PubMed ID: 12176583
    [No Abstract]   [Full Text] [Related]  

  • 3. Methods and outcomes of calcineurin inhibitor reduction or withdrawal in patients with chronic allograft nephropathy after the first year posttransplantation.
    Weir MR
    Transplant Proc; 2001 Jun; 33(4 Suppl):19S-28S. PubMed ID: 11406264
    [No Abstract]   [Full Text] [Related]  

  • 4. How to handle mycophenolate mofetil in combination with tacrolimus?
    Braun F; Canelo R; Schütz E; Shipkora M; Lorf T; Hanack U; Niedmann D; Armstrong VW; Oellerich M; Ringe B
    Transplant Proc; 1998 Dec; 30(8):4094-5. PubMed ID: 9865309
    [No Abstract]   [Full Text] [Related]  

  • 5. Co-administration of tacrolimus and mycophenolate mofetil in cadaveric renal transplant recipients.
    Vanrenterghem Y; Squifflet JP; Forsythe J; Heeman U; Bäckman L; Taube D; Morales JM; Ekberg H; van Hooff J; Zanker B; Dietl KH; Talbot D; Hauser I; Tydén G; Claesson K; Mühlbacher F
    Transplant Proc; 1998 Jun; 30(4):1290-1. PubMed ID: 9636523
    [No Abstract]   [Full Text] [Related]  

  • 6. Nephrotoxicity of calcineurin inhibitors: new therapeutic approaches.
    Abramowicz D; Wissing KM; Broeders N
    Transplant Proc; 2000 Feb; 32(1A Suppl):3S-5S. PubMed ID: 10686309
    [No Abstract]   [Full Text] [Related]  

  • 7. Conversion to rapamycin in renal allograft recipients with biopsy-proven calcineurin inhibitor-induced nephrotoxicity.
    Diekmann F; Waiser J; Fritsche L; Dragun D; Neumayer HH; Budde K
    Transplant Proc; 2001; 33(7-8):3234-5. PubMed ID: 11750386
    [No Abstract]   [Full Text] [Related]  

  • 8. [Initial experience with mycophenolate mofetil (RS 61443) after kidney transplantation].
    Friedrich J; Erhard J
    Zentralbl Chir; 1994; 119(1):48-9. PubMed ID: 8147160
    [No Abstract]   [Full Text] [Related]  

  • 9. Low-dose and rapid steroid withdrawal in renal transplant patients treated with tacrolimus and mycophenolate mofetil.
    Sola E; Alférez MJ; Cabello M; Burgos D; González Molina M
    Transplant Proc; 2002 Aug; 34(5):1689-90. PubMed ID: 12176537
    [No Abstract]   [Full Text] [Related]  

  • 10. Tacrolimus and mycophenolate mofetil in cadaveric renal transplant recipients. The European Multicentre Tacrolimus/MMF Study Group.
    Forsythe J
    Transplant Proc; 1999 Nov; 31(7A):69S-71S. PubMed ID: 10576049
    [No Abstract]   [Full Text] [Related]  

  • 11. Mycophenolate mofetil rescue therapy in liver transplant recipients.
    Gavlik A; Goldberg MG; Tsaroucha A; Webb MG; Khan RT; Weppler D; Nery JR; Khan MF; Zucker K; Viciana AL; Miller JA; Tzakis AG
    Transplant Proc; 1997; 29(1-2):549-52. PubMed ID: 9123124
    [No Abstract]   [Full Text] [Related]  

  • 12. A pilot study of cyclosporine withdrawal in stable renal transplant recipients after azathioprine-mycophenolate mofetil conversion.
    Thervet E; Morelon E; Ducloux D; Bererhi L; Noël LH; Janin A; Bedrossian J; Puget S; Chalopin JM; Mihatsch M; Legendre C; Kreis H
    Transplant Proc; 2000 Dec; 32(8):2778. PubMed ID: 11134800
    [No Abstract]   [Full Text] [Related]  

  • 13. A randomized trial of three renal transplant induction antibodies: early comparison of tacrolimus, mycophenolate mofetil, and steroid dosing, and newer immune-monitoring.
    Ciancio G; Burke GW; Gaynor JJ; Carreno MR; Cirocco RE; Mathew JM; Mattiazzi A; Cordovilla T; Roth D; Kupin W; Rosen A; Esquenazi V; Tzakis AG; Miller J
    Transplantation; 2005 Aug; 80(4):457-65. PubMed ID: 16123718
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kidney transplantation without calcineurin inhibitors using sirolimus.
    Stegall MD; Larson TS; Prieto M; Gloor J; Textor S; Nyberg S; Sterioff S; Ishitani M; Griffin M; Kremers W; Lund W; Schwab T; Cosio F; Velosa J
    Transplant Proc; 2003 May; 35(3 Suppl):125S-127S. PubMed ID: 12742483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. T-cell function in maintenance renal transplant patients receiving mycophenolate mofetil and steroids with or without tacrolimus.
    Canivet C; Böhler T; Galvani S; Therville N; Salvayre R; Durand D; Thomsen M; Rostaing L; Kamar N
    Transplant Proc; 2008 Dec; 40(10):3422-3. PubMed ID: 19100403
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of mycophenolate mofetil in renal transplant patients with cyclosporin toxicity.
    Shaheen FA; Sheikh IA
    Transplant Proc; 1999 Dec; 31(8):3294. PubMed ID: 10616481
    [No Abstract]   [Full Text] [Related]  

  • 17. Effect of mycophenolate mofetil in combination with standard immunosuppression on chronic transplant nephropathy: 1 year experience.
    Khachatryan N; Wauters JP; Vogel G
    Transplant Proc; 2002 May; 34(3):807-8. PubMed ID: 12034190
    [No Abstract]   [Full Text] [Related]  

  • 18. Tacrolimus/"low-dose" mycophenolate mofetil versus microemulsion cyclosporine/"low-dose" mycophenolate mofetil after kidney transplantation--1-year follow-up of a prospective, randomized clinical trial.
    Yang HC; Holman MJ; Langhoff E; Ulsh PJ; Dellock CA; Gupta M; Ahsan N
    Transplant Proc; 1999; 31(1-2):1121-4. PubMed ID: 10083501
    [No Abstract]   [Full Text] [Related]  

  • 19. Case 2: strategies to minimize the use of calcineurin inhibitors (CNIs).
    Hariharan S
    Transplantation; 2002 Sep; 74(5):746-7. PubMed ID: 12357988
    [No Abstract]   [Full Text] [Related]  

  • 20. Chronic allograft nephropathy: prospective randomised trial of cyclosporin withdrawal and mycophenolate mofetil or tacrolimus substitution.
    McGrath JS; Shehata M
    Transplant Proc; 2001 May; 33(3):2193-5. PubMed ID: 11377500
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.